AmTrust Financial Servs Stock (OTC: AFSIB)

Latest news for AmTrust Financial Servs (OTC:AFSIB) Stock

AmTrust Financial Services Inc is a multinational company that underwrites and provides property and casualty insurance products. The company specializes in coverage for small to mid-sized businesses, with a philosophical focus on niche diversity and low-hazard risk. AmTrust's business model strives to achieve its profit goals through geographic and product diversification. The company reports three business segments: Small Commercial Business, Specialty Risk and Extended Warranty, and Specialty Program. The vast majority of revenues is derived from its Small Commercial Business risk.

AMTRUST FINCL D/S PFD B by AmTrust Financial Services, Inc.

AmTrust Financial Services Inc

News

Federal Reserve

Fed's Powell Says No Change In Approach According To Political Calendars; Tools Never Used To Support Or Oppose A Politician Or Party; Sticking To Our Part Benefits All Americans; That's Our Belief And How We Always Operate; Any Actions Before, During, Or After Elections Will Be Based On Data And Risk Balance

TD Cowen analyst Matthew Ramsay maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Hold and raises the price target from $110 to $125.

Price Target

Analyst Ratings

QRVO

TD Cowen Maintains Hold on Qorvo, Raises Price Target to $125

Barclays analyst Julian Mitchell maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Underweight and lowers the price target from $217 to $215.

Barclays Maintains Underweight on Illinois Tool Works, Lowers Price Target to $215

TD Cowen analyst Matthew Ramsay maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Hold and raises the price target from $90 to $110.

SWKS

TD Cowen Maintains Hold on Skyworks Solutions, Raises Price Target to $110

Barclays analyst Julian Mitchell maintains Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) with a Equal-Weight and lowers the price target from $384 to $368.

HUBB

Barclays Maintains Equal-Weight on Hubbell, Lowers Price Target to $368

Fed's Powell Says Economy Not Extremely Bad, Just Pockets of Weakness; No Decision Made About Future Meetings

Barclays analyst Raimo Lenschow maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Equal-Weight and lowers the price target from $15 to $14.

FRSH

Barclays Maintains Equal-Weight on Freshworks, Lowers Price Target to $14

TD Cowen analyst Dan Brennan maintains GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) with a Buy and raises the price target from $46 to $50.

TD Cowen Maintains Buy on GeneDx Hldgs, Raises Price Target to $50

Goldman Sachs analyst Michael Ng reiterated a Neutral rating on Sofi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a <a href="https://www.benzinga.com/quote/SOFI/analyst-ratings">price target of $7.50</a>.
Ng noted Sofi Technologies upgraded its full-year <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b40032979/sofi-technologies-reports-net-revenue-of-599-million-and-net-income-of-17-million-for-q2-2024-mark" rel="noreferrer noopener">net income outlook</a> to $175 million—$185 million (versus $165 million—$175 million prior).
The analyst writes that adjusted EBITDA margins should continue to ramp throughout the year to 25% for the full year 2024 as the company optimizes its capital structure towards using lower-cost deposits as a funding source and improves unit economics on Credit Card and Investment products within the Financial Services segment.
Ng flagged that Financial Services growth was primarily due to improved monetization driven by higher deposits and spending levels within SoFi Money, more significant AUM within SoFi Invest, and an increase in Credit Card spending.
Sofi Technologies&#8217; deposits totaled $23.0 billion at quarter-end (versus $21.6 billion at fiscal 2024 first-quarter). Ng noted continued growth in deposits to reduce reliance on warehouse funding.
In the second quarter, lending revenue of $339 million beat Goldman Sachs&#8217; estimate and consensus of $284 million and $300 million, driven by a ~$1 billion beat in personal loan originations ($4.2 billion versus Goldman Sachs&#8217; estimate and consensus of $3.2 billion).
According to Sofi Technologies, it was able to drive origination growth while maintaining stringent underwriting standards.
In addition, the company&#8217;s second-quarter 90-day personal loan delinquency rate decreased to 64 bps (versus 72 bps in the first quarter).
Loan performance will remain in focus given that Sofi Technologies&#8217; personal loan annualized net charge-off rate of 3.84% (up versus 3.45% in the first quarter) was flattered by a $69 million delinquent loan asset sale in the quarter (~5.4% adjusted for this), the analyst said.
He said that personal loan origination volumes of $4.2 billion were well above Goldman Sachs and Visible Alpha&#8217;s consensus of $3.2 billion despite increasing concerns about consumer health. However, Sofi Technologies&#8217; customer base skews prime.
Separately, Sofi Technologies lowered its outlook for Tech Platform segment growth for 2024 to mid-to-high teens percentage (versus 20% yoy growth prior) as large deals take longer to ramp than expected, particularly in Latin America.
That said, other elements of Sofi Technologies&#8217; outlook were encouraging, including a raised outlook for Financial Services segment growth and deposits growth and Sofi Technologies&#8217; third consecutive quarter of positive GAAP net income.
Ng increased his fiscal 2024, 2025, and 2026 revenue estimates by 5% on average to reflect Sofi Technologies&#8217; latest outlook for personal lending &amp; financial services.
Ng projected fiscal 2024 revenue and EPS of $2.52 billion (prior $2.50 billion) and $0.11 (prior $0.08). The analyst expects fiscal 2025 revenue and EPS of $3.02 billion (prior $2.87 billion) and $0.25 (prior $0.12). He estimates fiscal 2026 revenue and EPS of $3.81 billion (prior $3.49 billion) and $0.56 (prior $0.35).
Price Action: SOFI shares are trading higher by 4.04% to $7.725 at last check Wednesday. 
Photo via Shutterstock

Analyst Color

Fintech news covering the emerging Financial Technology services sector

Fintech

Reiteration

Movers

Tech

Trading Ideas

SOFI

Sofi Tech's Lending And Financial Services Momentum Well Above Estimates: Goldman Sachs Raises Forecast

Barclays analyst David Anderson maintains Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) with a Underweight and raises the price target from $21 to $24.

Barclays Maintains Underweight on Oceaneering International, Raises Price Target to $24

Fed's Powell Says Many Perceived Pieces of Wisdom Haven't Worked, Situation Has Been Unique; Can't Look to History as a Guide to Future

Barclays analyst David Anderson maintains Expro Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPRO#NYSE">XPRO</a>) with a Overweight and raises the price target from $27 to $28.

XPRO

Barclays Maintains Overweight on Expro Gr Hldgs, Raises Price Target to $28

TD Cowen analyst Gary Taylor maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Buy and raises the price target from $80 to $89.

TD Cowen Maintains Buy on Centene, Raises Price Target to $89

WIIM

GTES

Gates Industrial shares are trading higher following Q2 earnings.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 400 points on Wednesday.
The Dow traded up 1.07% to 41,177.51 while the NASDAQ rose 3.10% to 17,678.79. The S&amp;P 500 also rose, gaining, 2.08% to 5,549.42.
Leading and Lagging Sectors Information technology shares jumped by 4.3% on Wednesday.
In trading on Wednesday, health care shares rose by just 0.1%.
Top Headline Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported better-than-expected earnings and sales results for its fourth quarter on Tuesday.
Intelligent Cloud segment revenue was $28.5 billion, up 19% year-over-year, while Azure and other cloud services revenue posted year-over-year growth of 29% last quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) shares shot up 40% to $186.83 after the company reported better-than-expected Q3 GAAP EPS and sales.</li>
<li>Shares of Modine Manufacturing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) got a boost, surging 24% to $122.84&nbsp;after the company reported better-than-expected first-quarter financial results.</li>
<li>Fiverr International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) shares were also up, gaining 22% to $26.78 after the company reported better-than-expected second-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares dropped 61% to $1.31 after the company announced a&nbsp;$10 million&nbsp;registered direct offering of 5 million&nbsp;shares of common stock with unregistered warrants at a price of&nbsp;$2&nbsp;per unit.</li>
<li>Shares of FibroGen, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) were down 45% to $0.5640. The company announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and said its Precision Promise study in metastatic pancreatic cancer did not meet its primary endpoint.</li>
<li>PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) was down, falling 35% to $11.05. The company announced clinical data from the first dose cohort of PGN-EDO51.</li>
</ul>
Commodities In commodity news, oil traded up 4.3% to $77.96 while gold traded up 1% at $2,476.40.
Silver traded up 1.5% to $28.945 on Wednesday, while copper rose 2.8% to $4.1965.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.80%, Germany's DAX rose 0.53% and France's CAC 40 gained 0.76%. Spain's IBEX 35 Index fell 1.23%, while London's FTSE 100 rose 1.13%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 gaining 1.49%, Hong Kong's Hang Seng Index jumping 2.01% and S&amp;P BSE Sensex gaining 0.35%.
Economics
<ul>
<li>U.S. pending home sales rose by 4.8% from the prior month in June compared to a revised contraction of 1.9%.</li>
<li>U.S. crude oil inventories declined by 3.436 million barrels in the week ended July 26th, above market estimates of a 1.6 million barrel draw.</li>
<li>Private businesses in the U.S. added 122,000 workers to their payrolls in July, versus a revised 155,000 in June.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: &#8216;I Would Pick Some Up Tomorrow</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">&#8216;</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

Markets

FGEN

FVRR

IMNN

MSFT

PEPG

POWL

Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher

Fed's Powell Says Well Positioned to Respond to Any Economic Weakness, Though Not Currently Observed; Plenty of Room to Act if Weakness Arises; Wage Gains Remain High; Data Indicates Labor Market Normalizing; Job Vacancies Still High by Historical Standards

During the last three months, 4 analysts shared their evaluations of First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $55.5, along with a high estimate of $60.00 and a low estimate of $50.00. This upward trend is apparent, with the current average reflecting a 5.21% increase from the previous average price target of $52.75.
<img src="https://www.benzinga.com/files/images/story/2024/1722452512_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of First Industrial Realty by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Caitlin Burrows</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$52.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to First Industrial Realty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Industrial Realty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for First Industrial Realty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of First Industrial Realty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Industrial Realty analyst ratings.</a>
<h2>Get to Know First Industrial Realty Better</h2>
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. First Industrial's real estate portfolio is comprised of light industrial properties, which are split between industrial and office space, and bulk warehouse properties generally located in business parks near transportation hubs. While light industrial buildings represent a share of First Industrial's holdings, bulk warehouses make up the majority of its portfolio's square footage. The company derives the vast majority of its revenue from rental income tied to medium-term leases. First Industrial's customers include manufacturing, retail, wholesale trade, distribution, and professional services companies.
<h3>Financial Milestones: First Industrial Realty's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: First Industrial Realty's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 7.83%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 31.24%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): First Industrial Realty's ROE stands out, surpassing industry averages. With an impressive ROE of 1.97%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): First Industrial Realty's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.99% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: First Industrial Realty's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down First Industrial Realty: 4 Analysts Share Their Views

Barclays analyst Pablo Monsivais maintains Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) with a Overweight and lowers the price target from $40 to $38.

VTMX

Barclays Maintains Overweight on Corporacion Inmobiliaria, Lowers Price Target to $38

Analysts' ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AtriCure, presenting an average target of $37.17, a high estimate of $53.00, and a low estimate of $26.00. Experiencing a 16.47% decline, the current average is now lower than the previous average price target of $44.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722452497_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into AtriCure's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AtriCure analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About AtriCure</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
<h3>Financial Insights: AtriCure</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: AtriCure's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 16.43%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: AtriCure's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -12.19%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.2%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRC

Navigating 6 Analyst Ratings For AtriCure

Maker's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mkr/usd">MKR</a>) price has increased 3.47% over the past 24 hours to $2,874.89. Over the past week, MKR has experienced an uptick of over 7.0%, moving from $2,664.68 to its current price. As it stands right now, the coin's all-time high is $6,292.31. 
The chart below compares the price movement and volatility for Maker over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1722452475_0.png" alt="price_chart" />
The trading volume for the coin has decreased 18.0% over the past week, while the overall circulating supply of the coin has decreased 0.28% to over 930 thousand. This puts its current circulating supply at an estimated 92.51% of its max supply, which is 1.01 million. The current market cap ranking for MKR is #36 at $2.67 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1722452475_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

AmTrust Financial Servs

News

Latest news for AmTrust Financial Servs (OTC:AFSIB) Stock